Dual specificity tyrosine-phosphorylation-regulated kinase
From Proteopedia
(Difference between revisions)
| (3 intermediate revisions not shown.) | |||
| Line 3: | Line 3: | ||
== Function == | == Function == | ||
| - | '''Dual specificity tyrosine-phosphorylation-regulated kinase''' (DYRK) is a member of a 5-member family of evolutionary conserved protein kinases. '''DYRK1A''' is associated with both neuropathological phenotypes and cancer susceptibility in patients with Down syndrome<ref>PMID:29985601</ref>. '''DYRK2''' is a 26S proteasome-regulating kinase<ref>PMID:26940127</ref>. | + | '''Dual specificity tyrosine-phosphorylation-regulated kinase''' (DYRK) is a member of a 5-member family of evolutionary conserved protein kinases. '''DYRK1A''' is associated with both neuropathological phenotypes and cancer susceptibility in patients with Down syndrome<ref>PMID:29985601</ref>. |
| + | *'''DYRK2''' is a 26S proteasome-regulating kinase<ref>PMID:26940127</ref>. | ||
| + | *'''DYRK3''' interacts with proteins associated with endoplasmic reticulum exit sites<ref>PMID:37643612</ref>. | ||
== Relevance == | == Relevance == | ||
| Line 12: | Line 14: | ||
The complex of human DYRK1A kinase domain with an inhibitor shows <scene name='84/842027/Cv/4'>numerous interactions</scene> between the protein ATP pocket and the inhibitor including with the <scene name='84/842027/Cv/5'>catalytic Lys residue</scene> and the <scene name='84/842027/Cv/6'>gatekeeper Phe residue</scene><ref>PMID:30095246</ref>. The gatekeeper Phe is a vital residue which is responsible for the selectivity of inhibitors<ref>PMID:30268771</ref>. | The complex of human DYRK1A kinase domain with an inhibitor shows <scene name='84/842027/Cv/4'>numerous interactions</scene> between the protein ATP pocket and the inhibitor including with the <scene name='84/842027/Cv/5'>catalytic Lys residue</scene> and the <scene name='84/842027/Cv/6'>gatekeeper Phe residue</scene><ref>PMID:30095246</ref>. The gatekeeper Phe is a vital residue which is responsible for the selectivity of inhibitors<ref>PMID:30268771</ref>. | ||
| - | |||
| - | </StructureSection> | ||
==3D structures of dual specificity tyrosine-phosphorylation-regulated kinase== | ==3D structures of dual specificity tyrosine-phosphorylation-regulated kinase== | ||
| - | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| - | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | + | [[Dual specificity tyrosine-phosphorylation-regulated kinase 3D structures]] | |
| - | + | </StructureSection> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | **[[5y86]] - hDYRK + phosphoTyr + phophoSer + phophoThr + phosphate + harmine<br /> | ||
| - | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Current revision
| |||||||||||
References
- ↑ Jarhad DB, Mashelkar KK, Kim HR, Noh M, Jeong LS. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics. J Med Chem. 2018 Nov 21;61(22):9791-9810. doi: 10.1021/acs.jmedchem.8b00185. Epub, 2018 Jul 20. PMID:29985601 doi:http://dx.doi.org/10.1021/acs.jmedchem.8b00185
- ↑ Guo X, Dixon JE. The 26S proteasome: A cell cycle regulator regulated by cell cycle. Cell Cycle. 2016;15(7):875-6. doi: 10.1080/15384101.2016.1151728. Epub 2016 Mar, 3. PMID:26940127 doi:http://dx.doi.org/10.1080/15384101.2016.1151728
- ↑ Gallo R, Rai AK, McIntyre ABR, Meyer K, Pelkmans L. DYRK3 enables secretory trafficking by maintaining the liquid-like state of ER exit sites. Dev Cell. 2023 Oct 9;58(19):1880-1897.e11. PMID:37643612 doi:10.1016/j.devcel.2023.08.005
- ↑ Tian S, Jia W, Lu M, Zhao J, Sun X. Dual-specificity tyrosine phosphorylation-regulated kinase 1A ameliorates insulin resistance in neurons by up-regulating IRS-1 expression. J Biol Chem. 2019 Dec 27;294(52):20164-20176. doi: 10.1074/jbc.RA119.010809. Epub, 2019 Nov 13. PMID:31723029 doi:http://dx.doi.org/10.1074/jbc.RA119.010809
- ↑ Czarna A, Wang J, Zelencova D, Liu Y, Deng X, Choi HG, Zhang T, Zhou W, Chang JW, Kildalsen H, Seternes OM, Gray NS, Engh RA, Rothweiler U. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors. J Med Chem. 2018 Aug 23. doi: 10.1021/acs.jmedchem.7b01847. PMID:30095246 doi:http://dx.doi.org/10.1021/acs.jmedchem.7b01847
- ↑ Banerjee S, Wei T, Wang J, Lee JJ, Gutierrez HL, Chapman O, Wiley SE, Mayfield JE, Tandon V, Juarez EF, Chavez L, Liang R, Sah RL, Costello C, Mesirov JP, de la Vega L, Cooper KL, Dixon JE, Xiao J, Lei X. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression. Proc Natl Acad Sci U S A. 2019 Nov 21. pii: 1912033116. doi:, 10.1073/pnas.1912033116. PMID:31754034 doi:http://dx.doi.org/10.1073/pnas.1912033116
- ↑ Czarna A, Wang J, Zelencova D, Liu Y, Deng X, Choi HG, Zhang T, Zhou W, Chang JW, Kildalsen H, Seternes OM, Gray NS, Engh RA, Rothweiler U. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors. J Med Chem. 2018 Aug 23. doi: 10.1021/acs.jmedchem.7b01847. PMID:30095246 doi:http://dx.doi.org/10.1021/acs.jmedchem.7b01847
- ↑ Arbones ML, Thomazeau A, Nakano-Kobayashi A, Hagiwara M, Delabar JM. DYRK1A and cognition: A lifelong relationship. Pharmacol Ther. 2019 Feb;194:199-221. doi: 10.1016/j.pharmthera.2018.09.010. Epub, 2018 Sep 28. PMID:30268771 doi:http://dx.doi.org/10.1016/j.pharmthera.2018.09.010
